Cytek Financial Statements From 2010 to 2025

CTKB Stock  USD 4.24  0.12  2.75%   
Cytek Biosciences financial statements provide useful quarterly and yearly information to potential Cytek Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cytek Biosciences financial statements helps investors assess Cytek Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cytek Biosciences' valuation are summarized below:
Gross Profit
111.1 M
Profit Margin
(0.03)
Market Capitalization
558.5 M
Enterprise Value Revenue
1.4849
Revenue
200.5 M
We have found one hundred twenty available fundamental signals for Cytek Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cytek Biosciences prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of March 19, 2025, Market Cap is expected to decline to about 807.7 M. In addition to that, Enterprise Value is expected to decline to about 721.1 M

Cytek Biosciences Total Revenue

153.3 Million

Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 336 K, Net Interest Income of 10.9 M or Interest Income of 10.9 M, as well as many indicators such as Price To Sales Ratio of 4.03, Dividend Yield of 0.0 or PTB Ratio of 2.26. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
  
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Cytek Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets415.7 M499.5 M207.3 M
Slightly volatile
Other Current Liabilities23.6 M33.1 M14 M
Slightly volatile
Total Current Liabilities46.3 M67.7 M30.5 M
Slightly volatile
Other Liabilities23.8 M34.9 M20.2 M
Slightly volatile
Property Plant And Equipment Net17.2 M28.1 M7.5 M
Slightly volatile
Current Deferred Revenue13.9 M25.5 M7.6 M
Slightly volatile
Accounts PayableM5.5 M2.9 M
Slightly volatile
Cash93.8 M98.7 M93 M
Slightly volatile
Non Current Assets Total58 M103.1 M24.9 M
Slightly volatile
Other Assets1.091.153.1 M
Slightly volatile
Cash And Short Term Investments264.3 M277.9 M123.5 M
Slightly volatile
Net Receivables42.4 M60.6 M27.1 M
Slightly volatile
Good Will9.9 M16.7 M4.3 M
Slightly volatile
Common Stock Total Equity83.9 K155.2 K54.3 K
Slightly volatile
Common Stock Shares Outstanding147.8 M132.8 M134.4 M
Slightly volatile
Liabilities And Stockholders Equity415.7 M499.5 M207.3 M
Slightly volatile
Non Current Liabilities Total60.2 M36.1 M83.2 M
Slightly volatile
Inventory41.5 M43.9 M27.1 M
Slightly volatile
Other Current Assets9.6 M14.1 MM
Slightly volatile
Total Liabilities93.9 M103.8 M112.9 M
Very volatile
Property Plant And Equipment Gross20.3 M36.8 M8.8 M
Slightly volatile
Total Current Assets357.7 M396.4 M182.4 M
Slightly volatile
Capital Stock103.6 K129 K53.6 K
Slightly volatile
Non Current Liabilities Other18.5 M11.4 M15.7 M
Slightly volatile
Net Working Capital311.4 M328.8 M151.9 M
Slightly volatile
Short Term Debt3.3 M3.5 MM
Pretty Stable
Intangible Assets21.1 M20.1 M4.8 M
Slightly volatile
Common Stock103.6 K129 K53.6 K
Slightly volatile
Property Plant Equipment16.5 M15.7 M4.9 M
Slightly volatile
Short and Long Term Debt Total11.7 M7.6 M6.3 M
Slightly volatile
Short and Long Term Debt2.4 M4.7 M2.5 M
Pretty Stable
Capital Surpluse476.6 M509.3 M434.7 M
Slightly volatile
Deferred Long Term Liabilities12.6 M15.1 M10.7 M
Slightly volatile
Long Term Debt1.3 M1.1 M2.1 M
Slightly volatile
Long Term Debt Total1.8 MM2.2 M
Slightly volatile

Cytek Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income10.9 M10.4 M2.5 M
Slightly volatile
Depreciation And Amortization11.1 M10.6 M2.6 M
Slightly volatile
Interest Expense5.5 M5.2 M1.1 M
Slightly volatile
Selling General Administrative28.8 M43.1 M15.4 M
Slightly volatile
Selling And Marketing Expenses33.3 M49.1 M19.2 M
Slightly volatile
Total Revenue153.3 M200.5 M94.4 M
Slightly volatile
Gross Profit88.2 M111.1 M51.7 M
Slightly volatile
Other Operating Expenses157.8 M221 M94.7 M
Slightly volatile
Research Development30.3 M39.4 M17.3 M
Slightly volatile
Cost Of Revenue65.1 M89.3 M42.7 M
Slightly volatile
Total Operating Expenses92.7 M131.6 M52 M
Slightly volatile
Reconciled Depreciation11 M10.5 M2.5 M
Slightly volatile
Non Operating Income Net Other6.8 M6.5 M1.6 M
Slightly volatile

Cytek Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation28.2 M26.8 M6.5 M
Slightly volatile
Begin Period Cash Flow196.8 M167.6 M104.8 M
Slightly volatile
Other Cashflows From Financing Activities2.1 M2.2 M29 M
Pretty Stable
Depreciation11 M10.5 M2.6 M
Slightly volatile
Capital Expenditures4.6 M3.5 M2.4 M
Slightly volatile
End Period Cash Flow93.8 M98.7 M93.5 M
Slightly volatile
Change To Netincome21 M20 M6.3 M
Slightly volatile
Dividends Paid922.4 K1.7 M424.7 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.034.241531.1253
Slightly volatile
Days Sales Outstanding79.09110105
Slightly volatile
Stock Based Compensation To Revenue0.140.13390.0371
Slightly volatile
Capex To Depreciation0.320.3362.5307
Slightly volatile
EV To Sales3.63.786730.3016
Slightly volatile
Inventory Turnover1.282.03561.5717
Pretty Stable
Days Of Inventory On Hand256179233
Pretty Stable
Payables Turnover13.2516.159714.0549
Slightly volatile
Sales General And Administrative To Revenue0.140.21510.1384
Slightly volatile
Research And Ddevelopement To Revenue0.150.19660.1668
Slightly volatile
Capex To Revenue0.02270.01760.0215
Slightly volatile
Cash Per Share1.442.1210.8919
Slightly volatile
Days Payables Outstanding25.9822.58726.9434
Slightly volatile
Intangibles To Total Assets0.07730.07370.0249
Slightly volatile
Current Ratio6.225.85915.1135
Slightly volatile
Receivables Turnover4.183.30853.5206
Slightly volatile
Capex Per Share0.0250.02690.0174
Slightly volatile
Revenue Per Share0.831.53010.6883
Slightly volatile
Interest Debt Per Share0.05430.09760.0289
Slightly volatile
Debt To Assets0.01820.01510.0169
Slightly volatile
Graham Number1.461.341.4479
Slightly volatile
Operating Cycle266290334
Slightly volatile
Days Of Payables Outstanding25.9822.58726.9434
Slightly volatile
Long Term Debt To Capitalization0.01970.01870.007
Slightly volatile
Quick Ratio5.495.21044.2339
Slightly volatile
Net Income Per E B T1.291.05611.0987
Pretty Stable
Cash Ratio1.391.45892.7346
Slightly volatile
Cash Conversion Cycle247267307
Pretty Stable
Days Of Inventory Outstanding256179233
Pretty Stable
Days Of Sales Outstanding79.09110105
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.880.86110.9561
Slightly volatile
Fixed Asset Turnover6.777.12640.483
Slightly volatile
Debt Ratio0.01820.01510.0169
Slightly volatile
Price Sales Ratio4.034.241531.1253
Slightly volatile
Asset Turnover0.480.40130.657
Slightly volatile
Gross Profit Margin0.460.55430.5204
Slightly volatile

Cytek Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap807.7 M850.2 M2.1 B
Slightly volatile
Enterprise Value721.1 M759.1 MB
Slightly volatile

Cytek Fundamental Market Drivers

Forward Price Earnings370.3704
Cash And Short Term Investments277.9 M

Cytek Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cytek Biosciences Financial Statements

Cytek Biosciences stakeholders use historical fundamental indicators, such as Cytek Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cytek Biosciences' assets and liabilities are reflected in the revenues and expenses on Cytek Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue25.5 M13.9 M
Total Revenue200.5 M153.3 M
Cost Of Revenue89.3 M65.1 M
Stock Based Compensation To Revenue 0.13  0.14 
Sales General And Administrative To Revenue 0.22  0.14 
Research And Ddevelopement To Revenue 0.20  0.15 
Capex To Revenue 0.02  0.02 
Revenue Per Share 1.53  0.83 
Ebit Per Revenue(0.10)(0.10)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.735
Earnings Share
(0.05)
Revenue Per Share
1.535
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.03)
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.